Castellon, V.E. (V. E.)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
Search Results
Now showing 1 - 1 of 1
- SEOM clinical guideline for the management of malignant melanoma (2017)(Springer, 2018) Gonzalez-Larriba, J.L. (José Luis); Soria, A. (Ainara); Espinosa, E. (E.); Martin-Algarra, S. (Salvador); Cao, M.G. (M. G.); Arance, A. (Ana); Marquez-Rodas, I. (Iván); Cruz, L. (L.) de la; Castellon, V.E. (V. E.); Berrocal, A. (Alfonso)All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.